RxDoctor Payments Data

Aleksei Plotnikov, MD

Internal Medicine · Greensboro, NCNPI 1083671036

Payments from drug & device makers

$14,244in general payments, 2019–2025

Across 911 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Boehringer Ingelheim$715
  • GSK$711
  • Amgen$709
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$14,244100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk137$1,624
AstraZeneca(2 entities)65$1,359
AbbVie(2 entities)85$1,178
Boehringer Ingelheim44$715
GSK44$711
Amgen(2 entities)47$709
Daiichi Sankyo Inc.34$708
Lilly USA, LLC40$613
Pfizer41$563
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC35$555
Johnson & Johnson(2 entities)30$342
Sunovion Pharmaceuticals Inc.35$315
Antares Pharma, Inc.12$277
Paratek Pharmaceuticals, Inc.9$260
Bayer18$253
Novartis15$252
Sanofi-aventis U.S. LLC13$217
Ironwood Pharmaceuticals, Inc12$205
Otsuka America Pharmaceutical, Inc.9$197
Biohaven Pharmaceuticals, Inc.8$187
Amarin Pharma, Inc.11$182
Shield Therapeutics Inc11$177
Astellas Pharma US Inc12$166
Merck10$154
Xeris Pharmaceuticals, Inc.10$153
Eisai Inc.9$148
Takeda Pharmaceuticals U.S.A., Inc.12$144
Esperion Therapeutics, Inc.8$142
Lundbeck LLC6$127
Abbott7$120
Kowa Pharmaceuticals America, Inc.8$111
Arbor Pharmaceuticals, Inc.6$101
Gilead5$94
Halozyme Inc4$87
Sumitomo Pharma America, Inc.5$73
Amneal Pharmaceuticals LLC3$71
Aimmune Therapeutics, Inc.3$67
Nestle Healthcare Nutrition Inc.5$66
Biohaven Pharmaceutical Holding Company Ltd.3$63
Dynavax Technologies Corporation4$61
Viatris Specialty LLC3$59
Dexcom, Inc.3$57
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$51
Irhythm Technologies, Inc.1$51
Actelion Pharmaceuticals US, Inc.2$48
Mylan Specialty L.p.2$47
Circassia Inc.3$47
Exact Sciences3$45
Forte Bio-pharma LLC1$32
Viiv Healthcare Company1$31
Teva Pharmaceuticals USA, Inc.2$24
Phathom Pharmaceuticals, Inc.1$22
Inspire Medical Systems, Inc.1$21
Vanda Pharmaceuticals Inc.1$20
Boston Scientific1$20
Fidia Pharma USA Inc.1$19
E.r. Squibb & Sons, L.L.C.1$19
Heartflow, Inc.1$17
Idorsia Pharmaceuticals US Inc1$17
Intra-sana Laboratories1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,244 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$136,953
Medicare patients
260
Services billed
4,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$165,512
EliquisApixaban141$125,548
RybelsusSemaglutide78$90,942
MounjaroTirzepatide59$72,832
OxycontinOxycodone Hcl24$66,234
JardianceEmpagliflozin48$53,869
XareltoRivaroxaban36$48,177
FarxigaDapagliflozin Propanediol39$38,483
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$32,047
LinzessLinaclotide31$30,380
CreonLipase/Protease/Amylase12$29,507
MyrbetriqMirabegron31$21,008
Spiriva RespimatTiotropium Bromide13$7,871
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen296$7,798
Fentanyl45$6,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,624$256,455219 claims
PfizerEliquis$563$125,548141 claims
Lilly USA, LLCMounjaro$613$72,83259 claims
AbbVieLinzess, Creon, Synthroid$1,178$66,700104 claims
Boehringer IngelheimJardiance, Spiriva Respimat$715$61,74161 claims
Johnson & JohnsonXarelto$342$48,17736 claims
AstraZenecaFarxiga, Symbicort$1,359$43,78854 claims
GSKTrelegy Ellipta$711$32,04729 claims
Astellas Pharma US IncMyrbetriq, Veozah$166$27,38943 claims
Kowa Pharmaceuticals America, Inc.Livalo$111$6,60614 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$71$3,598317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →